Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Plus Therapeutics (PSTV) Intangibles (2016 - 2025)

Plus Therapeutics (PSTV) has disclosed Intangibles for 16 consecutive years, with $374000.0 as the latest value for Q3 2025.

  • On a quarterly basis, Intangibles fell 27.1% to $374000.0 in Q3 2025 year-over-year; TTM through Sep 2025 was $374000.0, a 27.1% decrease, with the full-year FY2024 number at $469000.0, up 1016.67% from a year prior.
  • Intangibles was $374000.0 for Q3 2025 at Plus Therapeutics, down from $401000.0 in the prior quarter.
  • In the past five years, Intangibles ranged from a high of $557000.0 in Q2 2024 to a low of $33000.0 in Q1 2024.
  • A 5-year average of $206111.1 and a median of $103500.0 in 2022 define the central range for Intangibles.
  • Peak YoY movement for Intangibles: plummeted 58.23% in 2024, then skyrocketed 1218.18% in 2025.
  • Plus Therapeutics' Intangibles stood at $60000.0 in 2021, then skyrocketed by 56.67% to $94000.0 in 2022, then tumbled by 55.32% to $42000.0 in 2023, then skyrocketed by 1016.67% to $469000.0 in 2024, then decreased by 20.26% to $374000.0 in 2025.
  • Per Business Quant, the three most recent readings for PSTV's Intangibles are $374000.0 (Q3 2025), $401000.0 (Q2 2025), and $435000.0 (Q1 2025).